Download PDF
Planta Med 2014; 80(14): 1200-1209
DOI: 10.1055/s-0034-1383063
Reviews
Georg Thieme Verlag KG Stuttgart · New York

Assay Suitability for Natural Product Screening: Searching for Leads to Fight Alzheimerʼs Disease

Mervi Vasänge
Pharmaceutical Sciences, Åbo Akademi University, Turku, Finland
› Author Affiliations
Further Information

Publication History

received 13 April 2014
revised 20 August 2014

accepted 25 August 2014

Publication Date:
15 September 2014 (online)

   Permissions and Reprints

Abstract

Phenotypic and target-based approaches represent two principal strategies for identifying new bioactive compounds. In this review, differences between these approaches, as well as strengths and limitations thereof, are described by examples from the therapeutic area of Alzheimerʼs disease. Some of the central mechanisms of the disease that today are targets of screening campaigns are described. These mechanisms include acetylcholinesterase inhibition, amyloid-based approaches, and oxidative stress. Examples of assays using natural products, either as isolated pure compounds, unpurified or partially purified extracts, are given for each mechanism. Further, the article presents and discusses the pros and cons of both target-based and phenotypic approaches for the chosen mechanisms. In most cases, a thoroughly biology-driven selection of the used assays can be recommended, especially when taking into account the complexity of the disease in question. However, target-based assays also have their justification as long as there is an awareness of what the assay read-out stands for. A clear recommendation is thus for every researcher to critically consider the aim of their bioactivity screening efforts and to adopt the screening strategies most appropriate for the goals set.

Key words

phenotypic assay - target-based assay - reductionistic - Alzheimerʼs disease - acetylcholinesterase - amyloid - oxidative stress
 

  • References

  • 1 Swinney DC, Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011; 10: 507-519
    CrossrefPubMedGoogle Scholar
  • 2 Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J 2013; 280: 5957-5980
    CrossrefPubMedGoogle Scholar
  • 3 Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Brit J Pharmacol 2011; 162: 1239-1249
    CrossrefPubMedGoogle Scholar
  • 4 Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 2013; 1830: 3670-3695
    CrossrefPubMedGoogle Scholar
  • 5 Mishra BB, Tiwari VK. Natural products: An evolving role in future drug discovery. Eur J Med Chem 2011; 46: 4769-4807
    CrossrefPubMedGoogle Scholar
  • 6 Barker A, Kettle JG, Nowak T, Pease JE. Expanding medicinal chemistry space. Drug Discov Today 2013; 18: 298-304
    CrossrefPubMedGoogle Scholar
  • 7 López-Vallejo F, Giulianotti MA, Houghten RA, Medina-Franco JL. Expanding the medicinally relevant chemical space with compound libraries. Drug Discov Today 2012; 17: 718-726
    CrossrefPubMedGoogle Scholar
  • 8 Beutler JA. Natural products as a foundation for drug discovery. Curr Protoc Pharmacol 2009; 46: 1-9
    PubMedGoogle Scholar
  • 9 Schmitt EK, Moore CM, Krastel P, Petersen F. Natural products as catalysts for innovation: a pharmaceutical industry perspective. Curr Opin Chem Biol 2011; 15: 497-504
    CrossrefPubMedGoogle Scholar
  • 10 Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117
    CrossrefPubMedGoogle Scholar
  • 11 Bendlin BB, Carlsson CM, Gleason CE, Johnson SC, Sodhi A, Gallagher CL, Puglielli L, Engelman CD, Ries ML, Xu G, Wharton W, Asthana S. Midlife predictors of Alzheimerʼs disease. Maturitas 2010; 65: 131-137
    CrossrefPubMedGoogle Scholar
  • 12 Skape SD. Alzheimerʼs disease and amyloid: culprit or coincidence?. Int Rev Neurobiol 2012; 102: 277-316
    PubMedGoogle Scholar
  • 13 Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Ryan R, Walsh RR, Zhong K. Alzheimerʼs disease drug development: translational neuroscience strategies. CNS Spectr 2013; 18: 128-138
    CrossrefPubMedGoogle Scholar
  • 14 Misra S, Bikash B. Drug development status for Alzheimerʼs disease: present scenario. Neurol Sci 2013; 34: 831-839
    CrossrefPubMedGoogle Scholar
  • 15 Hardy JA, Higgins GA. Alzheimerʼs disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185
    CrossrefPubMedGoogle Scholar
  • 16 De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010; 6: 99-107
    CrossrefPubMedGoogle Scholar
  • 17 Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: 1-24
    PubMedGoogle Scholar
  • 18 Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 2013; 9: 25-34
    PubMedGoogle Scholar
  • 19 Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimerʼs disease: past, present and future. Neuropharmacol 2014; 76: 27-50
    CrossrefPubMedGoogle Scholar
  • 20 Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimerʼs disease. Lancet 1976; 8000: 1403
    PubMedGoogle Scholar
  • 21 Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progressing of Alzheimerʼs disease: Therapeutic implications. Expert Rev Neurother 2008; 8: 1703-1718
    CrossrefPubMedGoogle Scholar
  • 22 Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimerʼs disease. Curr Med Chem 2008; 15: 2433-2455
    CrossrefPubMedGoogle Scholar
  • 23 Tayeb HO, Yang HD, Price BH, Tazari FI. Pharmacotherapies for Alzheimerʼs disease: Beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134: 8-25
    CrossrefPubMedGoogle Scholar
  • 24 Sun X, Jin L, Ling P. Review of drugs for Alzheimerʼs disease. Drug Discov Ther 2012; 6: 285-290
    PubMedGoogle Scholar
  • 25 Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimerʼs disease. Prim Care Companion CNS Disord 2013; 15
    PubMedGoogle Scholar
  • 26 Ellman GL, Courtney KD, Anders Jr V, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
    CrossrefPubMedGoogle Scholar
  • 27 Järvinen P, Vuorela P, Hatakka A, Fallarero A. Potency determinations of acetylcholinesterase inhibitors using Ellmanʼs reaction based assay in screening: Effect of assay variants. Anal Biochem 2011; 408: 166-168
    CrossrefPubMedGoogle Scholar
  • 28 Marston A, Kissling J, Hostettmann K. A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase inhibitors in plants. Phytochem Anal 2002; 13: 51-54
    CrossrefPubMedGoogle Scholar
  • 29 Di Giovannia S, Borlozb A, Urbainb A, Marston A, Hostettmann K, Carrupta PA, Reista M. In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: Thin layer chromatography versus microplate methods. Eur J Pharm Sci 2008; 33: 109-119
    CrossrefPubMedGoogle Scholar
  • 30 Karlsson D, Fallarero A, Brunhofer G, Guzik P, Prinz M, Holzgrabe U, Erker T, Vuorela P. Identifying and characterization of diarylimidazoles as hybrid inhibitors of butyrylcholinesterase and amyloid beta fiblil formation. Eur J Pharm Sci 2012; 45: 169-183
    CrossrefPubMedGoogle Scholar
  • 31 Ingkaninan K, de Best CM, van der Heijden R, Hofte AJP, Karabatak B, Irth H, Tjaden UR, van der Greef J, Verpoorte R. High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. J Chromatog A 2000; 872: 61-73
    PubMedGoogle Scholar
  • 32 Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007; 14: 289-300
    CrossrefPubMedGoogle Scholar
  • 33 Orhan I, Sener B, Choudhary IM, Khalid A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J Ethnopharmacol 2004; 91: 57-60
    CrossrefPubMedGoogle Scholar
  • 34 Andersen A, Gauguin B, Gudiksen L, Jäger AK. Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity. J Ethnopharmacol 2006; 104: 418-422
    CrossrefPubMedGoogle Scholar
  • 35 Ferreira A, Proença C, Serralheiro MLM, Araujo MEM. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J Ethnopharmacol 2006; 108: 31-37
    CrossrefPubMedGoogle Scholar
  • 36 Mukherjee PK, Kumar V, Houghton PJ. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res 2007; 21: 1142-1145
    CrossrefPubMedGoogle Scholar
  • 37 Loizzo MR, Tundis R, Conforti F, Menichini F, Bonesi M, Nadjafi F, Frega NG, Menchini F. Salvia leriifolia Benth (Laminaceae) extract demonstrates antioxidant properties and cholinesterase inhibitory activity. Nutr Res 2010; 30: 823-830
    CrossrefPubMedGoogle Scholar
  • 38 Khan M, Elhussein SAA, Khan MM, Khan N. Anti-acetylcholinesterase activity of Piper sarmentosum by a continuous immobilized-enzyme assay. APCBEE Procedia 2012; 2: 199-204
    CrossrefPubMedGoogle Scholar
  • 39 Cespedes CL, Muñoz E, Salazar JR, Yamaguchi L, Werner E, Alarcon J, Kubo I. Inhibition of cholinesterase activity by extracts, fractions and compounds from Calceolaria talcana and C. integrifolia (Calceolariaceae: Scrophulariaceae). Food Chem Toxicol 2013; 62: 919-926
    CrossrefPubMedGoogle Scholar
  • 40 Lai DH, Yang ZD, Xue WW, Sheng J, Shi Y, Yao XJ. Isolation, characterization and acetylcholinesterase inhibitory activity of alkaloids from roots of Stemona sessilifolia . Fitoterapia 2013; 89: 257-264
    CrossrefPubMedGoogle Scholar
  • 41 Dvira H, Silmanb I, Harela M, Rosenberryc TL, Sussmana JL. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact 2010; 187: 10-22
    CrossrefPubMedGoogle Scholar
  • 42 Ryšlavá H, Doubnerová V, Kavan D, Vaněk O. Effect of posttranslational modifications on enzyme function and assembly. J Proteomics 2013; 92: 80-109
    CrossrefPubMedGoogle Scholar
  • 43 Massoulié J, Perrier N, Noureddine H, Liang D, Bon S. Old and new questions about cholinesterases. Chemical Biol Interact 2008; 75: 30-44
    PubMedGoogle Scholar
  • 44 Ramachandran S, Rami BR, Udgaonkar JB. Measurements of cysteine reactivity during protein unfolding suggest the presence of competing pathways. J Mol Biol 2000; 297: 733-745
    CrossrefPubMedGoogle Scholar
  • 45 Sakurada K, Ikegaya H, Ohta H, Akutsu T, Takatori T. Hydrolysis of an acetylthiocholine by pralidoxime iodide (2-PAM). Toxicol Lett 2006; 166: 255-260
    CrossrefPubMedGoogle Scholar
  • 46 Veloso AJ, Nagy PM, Zhang B, Dhar D, Liang A, Ibrahim T, Mikhaylichenko S, Aubert I, Kerman K. Miniaturized electrochemical system for cholinesterase inhibitor detection. Anal Chim Acta 2013; 774: 73-78
    CrossrefPubMedGoogle Scholar
  • 47 Min W, Wang W, Chen J, Wang A, Hu Z. On-line immobilized acetylcholinesterase microreactor for screening of inhibitors from natural extracts by capillary electrophoresis. Anal Bioanal Chem 2012; 404: 2397-2405
    CrossrefPubMedGoogle Scholar
  • 48 Yang ZD, Song ZW, Ren J, Yang MJ, Li S. Improved thin-layer chromatography bioautographic assay for the detection of actylcholinesterase inhibitors in plants. Phytochem Anal 2011; 22: 509-515
    CrossrefPubMedGoogle Scholar
  • 49 Mullane K, Williams M. Alzheimerʼs therapeutics: Continued clinical failures question the validity of the amyloid hypothesis – but what lies beyond?. Biochem Pharmacol 2013; 85: 289-305
    CrossrefPubMedGoogle Scholar
  • 50 Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 2000; 290: 150-153
    CrossrefPubMedGoogle Scholar
  • 51 Wang H, Li R, Shen Y. β-Secretase: its biology as a therapeutic target in diseases. TIPS 2013; 34: 215-225
    PubMedGoogle Scholar
  • 52 Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. γ-Secretase inhibitors and modulators. Biochim Biophys Acta 2013; 1828: 2898-2907
    CrossrefPubMedGoogle Scholar
  • 53 Jeon SY, Kwon SH, Seong YH, Bae K, Hur JM, Lee YY, Suh DY, Song KS. β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine 2007; 14: 403-408
    CrossrefPubMedGoogle Scholar
  • 54 Sasaki H, Miki K, Kinoshita K, Koyama K, Juliawaty LD, Achmad SA, Hakim EH, Kaneda M, Takahashi K. β-secretase (BACE-1) inhibitory effect of bioflavonoids. Bioorg Med Chem Lett 2010; 20: 4558-4560
    CrossrefPubMedGoogle Scholar
  • 55 Zhu Z, Li C, Wang X, Yang Z, Chen J, Hu L, Jiang H, Shen X. 2,2′,4′-trihydroxychalcone from Glycyrrhiza glabra as a new specific BACE1 inhibitor efficiently ameliorates memory impairment in mice. J Neurochem 2010; 114: 374-385
    CrossrefPubMedGoogle Scholar
  • 56 Tao J, Zhao J, Zhao Y, Cui Y, Fang W. BACE inhibitory flavanones from Balanophora involucrata Hook. f. Fitoterapia 2012; 83: 1386-1390
    CrossrefPubMedGoogle Scholar
  • 57 Hwang EM, Ryu YB, Kim HY, Kim DG, Hong SG, Lee JH, Curtis-Long MJ, Jeong SH, Park JY. BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens . Bioorg Med Chem 2008; 16: 6669-6674
    CrossrefPubMedGoogle Scholar
  • 58 Vassar R, Kovacs DM, Yan R, Wong PC. The β-Secretase enzyme BACE in health and Alzheimerʼs disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009; 29: 12787-12794
    CrossrefPubMedGoogle Scholar
  • 59 Small SA, Gandy S. Sorting through the cell biology of Alzheimerʼs disease: intracellular pathways to pathogenesis. Neuron 2006; 52: 15-31
    CrossrefPubMedGoogle Scholar
  • 60 Axelman K, Basun H, Winblad B, Lannfelt L. A large Swedish family with Alzheimerʼs disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation. Arch Neurol 1994; 51: 1193-1197
    CrossrefPubMedGoogle Scholar
  • 61 Zhu F, Wu F, Ma Y, Liu G, Li Z, Sun Y, Pei Z. Decrease in the production of beta-amyloid by berberine inhibition of the expression of betasecretase in HEK293 cells. BMC Neuroscience 2011; 12
    PubMedGoogle Scholar
  • 62 Kang IJ, Jeon YE, Yin XF, Nam JS, You SG, Hong MS, Jang BG, Kim MJ. Butanol extract of Ecklonia cava prevents production and aggregation of beta-amyloid, and reduces beta-amyloid mediated neuronal death. Food Chem Toxicol 2011; 49: 2252-2259
    CrossrefPubMedGoogle Scholar
  • 63 Cecchi C, Stefani M. The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. Biophys Chem 2013; 182: 30-43
    CrossrefPubMedGoogle Scholar
  • 64 Vepsäläinen S, Koivisto H, Pekkarinen E, Mäkinen P, Dobson G, McDougall GJ, Stewart D, Haapasalo A, Karjalainen RO, Tanila H, Hiltunen M. Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimerʼs disease. J Nutr Biochem 2013; 24: 360-370
    CrossrefPubMedGoogle Scholar
  • 65 Hage S, Kleinlen-Campard P, Octave JN, Quetin-Leclerq J. In vitro screening on β-amyloid peptide production of plants used in traditional medicine for cognitive disorders. J Ethnopharmacol 2010; 131: 585-591
    CrossrefPubMedGoogle Scholar
  • 66 Lee TH, Part YI, Han YH. Effect of mycelial extract of Clavicorona pyxidata on the production of amyloid β-peptide and the inhibition of endogenous β-secretase activity. J Microbiol 2006; 44: 665-670
    PubMedGoogle Scholar
  • 67 Findeis MA, Schroeder F, McKee TD, Yager D, Fraering PC, Creaser SP, Austin WF, Clardy J, Wang R, Selkoe D, Eckman CB. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa . ACS Chem Neurosci 2012; 21: 941-951
    PubMedGoogle Scholar
  • 68 Hall A, Patel TR. γ-Secretase modulators: current status and future directions. Prog Med Chem 2014; 53: 101-145
    PubMedGoogle Scholar
  • 69 Liu LF, Durairajan SSK, Lu JH, Koo I, Li M. In vitro screening on amyloid precursor protein modulation of plants used in ayurvedic and traditional Chinese medicine for memory improvement. J Ethnopharmacol 2012; 141: 754-760
    CrossrefPubMedGoogle Scholar
  • 70 Bignante EA, Heredia F, Morfini G, Lorenzo A. Amyloid β precursor protein as a molecular target for amyloid β-induced neuronal degeneration in Alzheimerʼs disease. Neurobiol Aging 2013; 34: 2525-2537
    CrossrefPubMedGoogle Scholar
  • 71 Haugabook SJ, Yager DM, Eckman EA, Golde TE, Younkin SG, Eckman CB. High throughput screens for the identification of compounds that alter the accumulation of the Alzheimerʼs amyloid peptide (Aβ). J Neurosci Meth 2001; 108: 171-179
    CrossrefPubMedGoogle Scholar
  • 72 Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: Structure–activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 2008; 1780: 819-825
    CrossrefPubMedGoogle Scholar
  • 73 Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimerʼs disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716
    CrossrefPubMedGoogle Scholar
  • 74 Dumont M, Flint Beal M. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology Medicine 2011; 51: 1014-1026
    CrossrefPubMedGoogle Scholar
  • 75 Sutherland GT, Chami B, Youssef P, Witting PK. Oxidative stress in Alzheimers disease: Primary villain or physiological by-product?. Redox Report 2013; 18: 134-141
    CrossrefPubMedGoogle Scholar
  • 76 López-Alarcón C, Denicola A. Evaluating the antioxidant capacity of natural products: A review on chemical and cellular based assays. Anal Chim Acta 2013; 763: 1-10
    CrossrefPubMedGoogle Scholar
  • 77 Magalhães LM, Segundo MA, Reis S, Lima JLFC. Methodological aspects about in vitro evaluation of antioxidant properties. Anal Chim Acta 2008; 613: 1-19
    CrossrefPubMedGoogle Scholar
  • 78 Niki E. Assessment of antioxidant capacity in vitro and in vivo . Free Radical Biol Med 2010; 49: 503-515
    CrossrefPubMedGoogle Scholar
  • 79 Kamdem JP, Adeniran A, Boligon AA, Klimaczewski CV, Elekofehinti OO, Hassan W, Ibrahim M, Waczuk EP, Meinerz DF, Athayde ML. Antioxidant activity, genotoxicity and cytotoxicity evaluation of lemon balm (Melissa officinalis L.) ethanolic extract: Its potential role in neuroprotection. Ind Crops Prod 2013; 51: 26-34
    CrossrefPubMedGoogle Scholar
  • 80 Venkatachalam RN, Singh K, Marar T. Phytochemical screening and in vitro antioxidant activity of Psidium guaja . Free Rad Antiox 2012; 2: 31-36
    CrossrefPubMedGoogle Scholar
  • 81 Arruda M, Viana H, Rainha N, Neng NR, Rosa JS, Nogueira JMF, do Carmo Barreto M. Anti-acetylcholinesterase and antioxidant activity of essential oils from Hedychium gardnerianum Sheppard ex Ker-Gawl. Molecules 2012; 17: 3082-3092
    CrossrefPubMedGoogle Scholar
  • 82 Orhan IE, Suntar IP, Akkol EK. In vitro neuroprotective effects of the leaf and fruit extracts of Juglans regia L. (walnut) through enzymes linked to Alzheimerʼs disease and antioxidant activity. Int J Food Sci Nutr 2011; 62: 781-786
    CrossrefPubMedGoogle Scholar
  • 83 Wong DZH, Kadir HA, Ling SK. Bio-assay guided isolation of neuroprotective compounds from Loranthus parasiticus against H2O2-induced oxidative damage in NG108–15 cells. J Ethnopharmacol 2012; 139: 256-264
    CrossrefPubMedGoogle Scholar
  • 84 Zhao Y, Dou J, Wu T, Aisa HA. Investigating the antioxidant and acetylcholinesterase inhibition activities of Gossypium herbaceam . Molecules 2013; 18: 951-962
    CrossrefPubMedGoogle Scholar
  • 85 Xiao Z, Huang C, Wu J, Sun L, Hao W, Leung LK, Huang J. The neuroprotective effects of ipriflavone against H2O2 and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells. Eur J Pharmacol 2013; 721: 286-293
    CrossrefPubMedGoogle Scholar
  • 86 Custódio L, Patarra J, Alberício F, Neng NR, Nogueira JMF, Romano A. Extracts from Quercus sp. acorns exhibit in vitro neuroprotective features through inhibition of cholinesterase and protection of the human dopaminergic cell line SH-SY5Y from hydrogen peroxide-induced cytotoxicity. Ind Corps Prod 2013; 45: 114-120
    PubMedGoogle Scholar
  • 87 Ha SK, Moon E, Ju MS, Kim DH, Ryu JH, Oh MS, Kim SY. 6-shogaol, a ginger product, modulates neuroinflammation: A new approach to neuroprotection. Neuropharmacol 2012; 63: 211-223
    CrossrefPubMedGoogle Scholar
  • 88 Figuera-Losasa M, Rojas C, Slusher BS. Inhibition of microglia activation as a phenotypic assay in early drug discovery. JBS 2014; 19: 17-31
    PubMedGoogle Scholar
  • 89 Masters CL, Simms G, Weinman NA, Multhaupt G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 1985; 83: 4245-4249
    PubMedGoogle Scholar
  • 90 Hardy J. Framing β-amyloid. Nat Gen 1992; 1: 233-234
    CrossrefPubMedGoogle Scholar
  • 91 Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in Alzheimerʼs disease from risk factors to prevention. Biochem Pharmacol 2014; 88: 661-670
    CrossrefPubMedGoogle Scholar
  • 92 Macarrón R, Hertzberg RP. Design and implementation of high throughput screening assays. Mol Biotechnol 2011; 47: 270-285
    CrossrefPubMedGoogle Scholar
  • 93 Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DL. Modern phenotypic drug discovery is a viable, neoclassic strategy. J Med Chem 2012; 55: 4527-4538
    CrossrefPubMedGoogle Scholar
  • 94 Butera J. Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents. J Med Chem 2013; 56: 7715-7718
    CrossrefPubMedGoogle Scholar
  • 95 Swinney DC. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen 2013; 18: 1186-1192
    CrossrefPubMedGoogle Scholar
  • 96 Lee LA, Berg EL. Neoclassic drug discovery: The case for lead generation using phenotypic and functional approaches. J Biomol Screen 2013; 18: 1145-1155
    PubMedGoogle Scholar
  • 97 Winquist RJ, Mullane K, Williams M. The fall and rise of pharmacology – (Re)defining the discipline?. Biochem Pharmacol 2014; 87: 4-24
    CrossrefPubMedGoogle Scholar